SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
43.74
+0.54 (+1.25%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close43.20
Open44.08
Bid0.00 x 0
Ask0.00 x 0
Day's Range43.48 - 44.08
52 Week Range39.42 - 50.65
Volume3,066,059
Avg. Volume1,442,354
Market Cap109.479B
Beta0.75
PE Ratio (TTM)10.01
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.64 (3.68%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes10 hours ago

    Sanofi And Celgene Are The Latest To Acquire Promising Biotechs

    By investing in biotech companies before they became acquisition targets, Todd’s HIBEV fund returned more than 30% last year. On Monday, Sanofi and Celgene announced multi-billion dollar biotech acquisitions showing that this investment strategy continues to have legs.

  • Benzinga12 hours ago

    Pharma M&A Picks Up Momentum

    After a lull in 2016 and 2017, M&A activity seems to be picking up pace in 2018.. The action seems to be even more brisk in the pharma sector, as companies attempt to give depth to their product portfolio ...

  • Novartis on the Street: Analyst Ratings and Recommendations
    Market Realist15 hours ago

    Novartis on the Street: Analyst Ratings and Recommendations

    Novartis’s 4Q17 Earnings: Behind the Expectations

  • Regeneron's Dupixent Receives MHLW Nod for Label Expansion
    Zacks16 hours ago

    Regeneron's Dupixent Receives MHLW Nod for Label Expansion

    Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

  • Reading the Estimates for Novartis’s Alcon in 4Q17
    Market Realist17 hours ago

    Reading the Estimates for Novartis’s Alcon in 4Q17

    Novartis’s 4Q17 Earnings: Behind the Expectations

  • What’s Expected of Novartis’s Sandoz Segment in 4Q17?
    Market Realist18 hours ago

    What’s Expected of Novartis’s Sandoz Segment in 4Q17?

    Novartis’s 4Q17 Earnings: Behind the Expectations

  • The Wall Street Journalyesterday

    [$$] High Prices Won’t Deter Biotech Deals

    Expect more expensive biotech acquisitions after two high-priced deals were announced Monday.

  • The Wall Street Journalyesterday

    [$$] Big Drugmakers Pay Big Prices for Promising Biotechs

    Celgene and Sanofi are the latest big drugmakers willing to pay hefty premiums for acquisitions amid an increasingly scarce roster of companies with promising products.

  • 3 Stocks for Warren Buffett Fans
    Motley Foolyesterday

    3 Stocks for Warren Buffett Fans

    If you like the Oracle of Omaha, you'll love these three companies.

  • Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc.
    Motley Foolyesterday

    Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc.

    Find out why shareholders had to endure a roller-coaster ride to nowhere.

  • What Happened in the Stock Market Today
    Motley Foolyesterday

    What Happened in the Stock Market Today

    On a record day for the market, Halliburton reported a strong quarter and Sanofi is buying Bioverativ in a big biotech deal.

  • Will Biotech's Merger 'Spigot' Turn On After Juno, Bioverativ?
    Investor's Business Dailyyesterday

    Will Biotech's Merger 'Spigot' Turn On After Juno, Bioverativ?

    Celgene will buy Juno Therapeutics for $9 billion and French pharma Sanofi will pay $11.6 billion for Bioverativ.

  • Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ
    Investor's Business Dailyyesterday

    Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ

    Celgene will acquire Juno Therapeutics for $9 billion. Sanofi reached a deal Monday to buy hemophilia drugmaker Bioverativ for $11.6 billion, or $105 a share.

  • TheStreet.comyesterday

    Dow, S&P 500 and Nasdaq Post New Records as Senate Reaches Deal to End Shutdown

    Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.

  • InvestorPlace2 days ago

    Is Sanofi’s Bioverative Inc Buyout Just the Start?

    Bioverativ Inc (NASDAQ:BIVV), spun out of Biogen Inc. (NASDAQ:BIIB) less than a year ago, drew an $11.6 billion bid from Sanofi SA (ADR) (NYSE:SNY) on Jan. 22, a 64% premium over its closing price on Jan. 19. The bid, $105 per share, could be just the start of a shopping bonanza as big pharma companies seek to grow their drug pipelines through acquisitions of smaller biotech companies.

  • Behind Novartis’s 4Q17 Estimates: Innovative Medicines
    Market Realist2 days ago

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.

  • Reuters2 days ago

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    The acquisitions will fuel expectations for a busy year of mergers and acquisitions (M&A) as large drugmakers snap up promising assets from smaller rivals to help revive growth. Sanofi agreed to buy U.S. haemophilia expert Bioverativ for $11.6 billion, its biggest deal for seven years, while Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics it does not already own.

  • Reuters2 days ago

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    The acquisitions will fuel expectations for a busy year of mergers and acquisitions (M&A) as large drugmakers snap up promising assets from smaller rivals to help revive growth. Sanofi agreed to buy U.S. hemophilia expert Bioverativ for $11.6 billion, its biggest deal for seven years, while Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics it does not already own.

  • Reuters2 days ago

    New drugs recast $10 billion haemophilia market as Sanofi swoops in

    Sanofi is placing a big bet on the $10 billion-a-year haemophilia market at a testing time, as scientific advances overhaul traditional approaches to treating the rare uncontrolled bleeding disorder. The French drugmaker's decision to buy U.S. haemophilia specialist Bioverativ for $11.6 billion exposes it to competition from Roche's new drug Hemlibra and looming threats from gene therapy. It also offers a potential launchpad for Sanofi's own experimental medicine fitusiran.

  • Reuters2 days ago

    Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

    French healthcare group Sanofi (SASY.PA) has agreed to buy U.S. haemophilia specialist Bioverativ (BIVV.O) for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. Several analysts said the deal looked expensive, given uncertainties in the haemophilia market due to the arrival of new drug treatments, and Sanofi shares fell 4 percent on Monday, the worst performance on France's benchmark CAC-40 index. The move comes at a time of renewed interest by large drugmakers in smaller biotech firms, with Celgene (CELG.O) also announcing a $9 billion deal to buy Juno Therapeutics (JUNO.O), and predictions by some experts that 2018 will see a substantial pick-up in mergers and acquisitions.

  • Health-Care Deals Fire Up With Drug Giants Facing Price Pressure
    Bloomberg2 days ago

    Health-Care Deals Fire Up With Drug Giants Facing Price Pressure

    The new year’s health-care deals began to snowball as Sanofi and Celgene Corp. scooped up assets that promise to offset pricing pressure for some of their top-selling drugs.

  • Asian shares rise on global growth hopes, US shutdown's end
    Associated Pressyesterday

    Asian shares rise on global growth hopes, US shutdown's end

    Asian stock markets posted strong gains on Tuesday, as an upbeat forecast for global economic growth and the end of the U.S. government shutdown helped lift sentiment. KEEPING SCORE: Japan's benchmark ...

  • Biotech's $20 Billion Merger Monday Results May Disappoint
    Bloomberg2 days ago

    Biotech's $20 Billion Merger Monday Results May Disappoint

    Both Celgene and Sanofi seem to have been pressured into iffy deals.

  • TheStreet.com2 days ago

    Dow, S&P 500 and Nasdaq Shake Off Government Shutdown to Trade Higher

    Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.

  • Merger Monday for biotech
    CNBC Videos2 days ago

    Merger Monday for biotech

    CNBC's Meg Tirrell reports on two major deals in the biotech space: Sanofi buying Bioverativ and Celgene buying Juno Therapeutics.